December 11, 2018 Mylan and Rite Aid are facing a class action that claims the companies respectively manufactured and sold generic valsartan medications despite possessing knowledge that the drugs were contaminated with probable carcinogen N-nitrosodiethylamine (NDEA).
September 6, 2017 Thirteen new cases have been filed in Pennsylvania federal court as part of a multidistrict litigation accusing numerous pharmaceutical companies of conspiring to fix the prices of generic drugs.
July 24, 2017 Mylan Pharmaceuticals, Inc. and Mylan Specialty, L.P. are facing another proposed class action – this time filed in Alabama – alleging that they charged consumers unlawfully high prices for their EpiPen products.
June 6, 2017 Seven more lawsuits have been filed this week as part of a multidistrict litigation that accuses the pharmaceutical companies of conspiring to fix generic drug prices.
June 1, 2017 Six more lawsuits have been added to a multidistrict litigation that claims various pharmaceutical companies have conspired to fix the price of generic drugs.